[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100431561":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":36,"locations":42,"responsibleParty":61,"collaborators":63,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":31,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":31,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":89,"overallStatus":44,"whyStopped":31,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Stanford University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A: fluoxetine then fluoxetine plus dextromethorphan","EXPERIMENTAL","Group A participants will take fluoxetine 20mg (or prior dose) daily for 4 weeks, and will then continue fluoxetine while adding over the counter dextromethorphan, with doses increasing weekly as tolerated, for 4 weeks.",[13,14],"Drug: Fluoxetine","Drug: Dextromethorphan",{"label":16,"type":10,"description":17,"interventionNames":18},"Group B: fluoxetine plus dextromethorphan then fluoxetine","Group B participants will take fluoxetine 20mg (or prior dose) daily together with over the counter dextromethorphan, with doses increasing weekly as tolerated, for 4 weeks, and then will stop dextromethorphan, continuing fluoxetine alone for 4 weeks.",[13,14],[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Fluoxetine","Fluoxetine 20mg (or previously prescribed dose) will be taken once daily by mouth for 8 weeks",[9,16],[26],"Prozac",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Dextromethorphan","Dextromethorphan, an over-the-counter cough suppressant, will be taken by mouth twice daily for four weeks of the study, starting at 15mg per dose, and increasing weekly as tolerated to a maximum of 60mg per dose.",[9,16],null,[33],{"name":34,"affiliation":5,"role":35},"Peter J van Roessel, MD PhD","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":31,"email":41},"Alessa Gaeta, BA","CONTACT","650 497 2578","ocdresearch@stanford.edu",[43],{"facility":5,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Stanford","California","94304","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-122.16608,37.42411,{"lat":54,"lon":53},[57,59],{"name":38,"role":39,"phone":58,"phoneExt":31,"email":41},"650-723-4095",{"name":60,"role":35,"phone":31,"phoneExt":31,"email":31},"Peter van Roessel, MD, PhD",{"type":35,"investigatorFullName":34,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Clinical Associate Professor",[64],{"name":65,"class":66},"Avy L. & Roberta L. Miller Foundation","UNKNOWN","100431561","phase-2-study-of-dextromethorphan-in-ocd-and-related-disorders-100431561",false,"NCT04899687","Study of Dextromethorphan in OCD and Related Disorders","Fluoxetine\u002FDextromethorphan in Obsessive-Compulsive and Related Disorders: an Open-Label Crossover Pilot Study","Inclusion Criteria:\n\n* Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD)\n* Living within California\n* Capacity to provide informed consent\n\nExclusion Criteria:\n\n* Current bipolar disorder or psychotic disorder\n* Active moderate or severe substance use disorder, lifetime severe substance use disorder\n* Pregnant or nursing women\n* Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start\n* Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start","ALL","18 Years","65 Years",{"count":78,"type":79},60,"ESTIMATED","INTERVENTIONAL",[82],"PHASE2","The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.",[85,86,87,88],"Obsessive-Compulsive Disorder","Illness Anxiety Disorder","Body Dysmorphic Disorders","Somatic Symptom Disorder",[90,91,92,93,22,28],"OCD","BDD","IAD","SSD","2026-05-18",{"date":96,"type":97},"2026-05-20","ACTUAL",{"date":99,"type":97},"2022-01-20",{"date":101,"type":79},"2028-12-01",{"name":5,"class":6},1]